跳至主要内容
临床试验/NL-OMON50547
NL-OMON50547已完成2 期

ZOledronic acid as DIseAse-modifying drug in Knee osteoarthritis (ZODIAK) - ZODIAK

niversitair Medisch Centrum Utrecht0 个研究点目标入组 86 人开始时间: 待定最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
86

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • - Age between 40 and 70 years.
  • - Primary tibiofemoral (TF) knee OA according to clinical and radiographic ACR
  • criteria. When two knees are eligible, the most painful knee is chosen as index
  • knee. When knees are equally painful the index knee will be selected randomly.
  • The most affected compartment (MAC) of the index is defined as the TF
  • compartment with the most radiographic joint space loss.
  • - Pain in the index knee on at least 50% of the days of the previous month (NRS
  • between 4/10 and 8/10).
  • - At least one bone marrow lesion (BML) in the MAC of the index knee on MRI, as
  • judged by a trained researcher. A BML is defined on T2-weighted MRI sequences
  • as a zone of altered signal intensity in the bone and marrow, located
  • immediately beneath the articular cartilage and visible on at least two
  • consecutive slices.

排除标准

  • - Severe structural OA of the MAC of the index knee on plain radiograph: grade
  • 3 radiographic joint space narrowing of the index knee, according to the
  • Osteoarthritis Research Society International atlas.
  • - Planned or expected surgery of index knee in the next 2 years (physician
  • - Intra-articular injection into the index knee: glucocorticoids, hyaluronic
  • acid, or platelet-rich plasma within the last 6 months.
  • - Knee pain from other causes than knee OA (e.g. fibromyalgia)
  • - Secondary OA, such as secondary to inflammatory joint disease, significant
  • trauma, metabolic disease, and/or extreme varus or valgus position of the knee
  • (i.e. more than 10º).
  • - Other self-reported diseases with potential effects on current bone
  • metabolism (e.g. thyroid or parathyroid disease, malignancy, bone fracture
  • within past 6 months).
  • - Self-reported disease that limits intestinal absorptive capacity (e.g. celiac
  • disease or short bowel syndrome).
  • - Previous allergic reaction to zoledronic acid, another bisphosphonate, or
  • other substances in the solute.
  • - Previous and/or current use of bisphosphonates, denosumab, teriparatide,
  • strontium ranelate, calcitonin and/or raloxifene.
  • - Current use of loop diuretics, glucocorticoids, aminoglycoside antibiotics.
  • - Uncontrolled or actively treated dental disease and/or otitis.
  • - Current or previous atrial fibrillation.
  • - Abnormal blood tests: serum ionized calcium higher than 1.32 mmol/l or lower
  • than 1.15 mmol/l, serum (25OH) vitamin D lower than 50 nmol/l, or estimated
  • creatinine clearance lower than 60 ml/min.
  • - Contraindications to MRI (e.g. claustrophobia, MRI-incompatible
  • devices/implants/foreign objects).
  • - Insufficient ability to communicate in Dutch.
  • - Pregnancy or lactation.
  • - Other factors that prevent subjects from adhering to the protocol.

研究者

发起方
niversitair Medisch Centrum Utrecht

相似试验